Eli Lilly and Company has become a key player in the production of tirzepatide, a groundbreaking medication for type 2 diabetes. Tirzepatide, a dual GIP and GLP-1 receptor agonist, showcases significant capacity to improve glycemic control and reduce cardiovascular risks. The intricate production